The Latest Cannabis Articles from Streetwise Reports


Cannabis Firm Increases YOY Revenue By 352% in 2021

Research Report
  ()
The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report.
Tags:  Cannabis

Cannabis Infused Beverage Company Stock in 'Very Good Spot' to Purchase

Contributed Opinion
  ()
Technical analyst Clive Maund explains why he rates this company a strong speculative buy.
Tags:  Cannabis

Q1 Results of Cannabis Firm Down YoY

Research Report
  ()
Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report.
Tags:  Cannabis

Cannabis Cos. Expected to Post Better Revenues As of Q2/22

  ()
Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report.
Tags:  Cannabis

GNC to Distribute Products for CBD Co.

Research Report
  ()
The agreement with GNC is a step toward Charlotte's Web Holdings' goals of expanding consumer access to its products and becoming cash flow positive this year, noted a ROTH Capital Partners report.
Tags:  Cannabis

US Cannabis Firm in 'State of Flux'

Research Report
  ()
With several market factors working against Stem Holdings, its future is uncertain, noted a Noble Capital Markets report.
Tags:  Cannabis

Showing Results: 1 to 6 of 6

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"RHT is rated an Immediate Buy here."
– Clive Maund, CliveMaund.com
"We have a Buy recommendation on QPM."
– Chris Temple, The National Investor
"We have a Buy recommendation on JEV."
– Chris Temple, The National Investor
"We have a Buy recommendation on PGE."
– Chris Temple, The National Investor